Peg Interferon α-2b for Relapsed Hematological Malignancies After Allo-HSCT
NCT02634294
·
clinicaltrials.gov ↗
PHASE2,PHASE3
Phase
COMPLETED
Status
30
Enrollment
OTHER
Sponsor class
Conditions
Hematological Neoplasms
Recurrence
Interventions
DRUG:
Peg interferon alfa-2b
Sponsor
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine